برنامج تطوير مهنة الصيدلة - PPDPROGRAM

➡️Zulresso (brexanolone) Injection Date of Approval: March 19, 2019 Company: Sage Therapeutics Treatment for: Postpartum Depression Zulresso (brexanolone) is a gamma-aminobutyric acid A (GABAA) receptor positive allosteric modulator indicated for the treatment of postpartum depression (PPD). https://t.me/ppdprogram

➡️Egaten (triclabendazole) Tablets Date of Approval: February 13, 2019 Company: Novartis Treatment for: Fascioliasis Egaten (triclabendazole) is a benzimidazole anthelmintic indicated for the treatment of fascioliasis, a neglected tropical disease (NTD) caused by liver flukes Fasciola hepatica and Fasciola gigantica. https://t.me/ppdprogram

➡️Wixela Inhub (fluticasone propionate and salmeterol) Inhalation Powder Date of Approval: January 30, 2019 Company: Mylan N.V. Treatment for: Asthma, COPD Wixela Inhub (fluticasone propionate and salmeterol) is a corticosteroid and long-acting beta2-adrenergic agonist (LABA) combination indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Wixela Inhub is the first approved generic version of Advair Diskus. https://t.me/ppdprogram

➡️Gemtesa (vibegron) Tablets Date of Approval: December 23, 2020 Company: Urovant Sciences Treatment for: Overactive Bladder Gemtesa (vibegron) is a once-daily beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. https://t.me/ppdprogram

➡️Orgovyx (relugolix) Tablets Date of Approval: December 18, 2020 Company: Myovant Sciences Treatment for: Prostate Cancer Orgovyx (relugolix) is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer. https://t.me/ppdprogram

➡️Thyquidity (levothyroxine sodium) Oral Solution Date of Approval: November 30, 2020 Company: Vertice Pharma Thyquidity (levothyroxine sodium) is a liquid dosage form of levothyroxine for the treatment of hypothyroidism. https://t.me/ppdprogram

➡️Imcivree (setmelanotide) Injection Date of Approval: November 25, 2020 Company: Rhythm Pharmaceuticals, Inc. Treatment for: Obesity Imcivree (setmelanotide) is a melanocortin 4 (MC4) receptor agonist for chronic weight management of obesity caused by proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency; or Bardet-Biedl syndrome. https://t.me/ppdprogram

➡️Oxlumo (lumasiran) Injection Date of Approval: November 23, 2020 Company: Alnylam Pharmaceuticals, Inc. Treatment for: Primary Hyperoxaluria Oxlumo (lumasiran) is a HAO1-directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. https://t.me/ppdprogram

➡️Sesquient (fosphenytoin sodium) for Injection Date of Approval: November 5, 2020 Company: Sedor Pharmaceuticals, LLC Treatment for: Status Epilepticus Sesquient (fosphenytoin sodium for injection) is a Captisol-enabled™, room-temperature stable formulation of fosphenytoin sodium indicated for the treatment of status epilepticus in adults and children. https://t.me/ppdprogram

➡️Bronchitol (mannitol) Inhalation Powder Date of Approval: October 30, 2020 Company: Chiesi USA, Inc. Treatment for: Cystic Fibrosis Bronchitol (mannitol) is an inhaled dry powder formulation of the sugar alcohol mannitol indicated as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. https://t.me/ppdprogram

➡️Eysuvis (loteprednol etabonate) Ophthalmic Suspension Date of Approval: October 26, 2020 Company: Kala Pharmaceuticals, Inc. Treatment for: Dry Eye Disease Eysuvis (loteprednol etabonate) is an ophthalmic corticosteroid formulation for the temporary relief of signs and symptoms of dry eye disease. https://t.me/ppdprogram

➡️Sogroya (somapacitan-beco) Injection Date of Approval: August 28, 2020 Company: Novo Nordisk Treatment for: Adult Human Growth Hormone Deficiency Sogroya (somapacitan-beco) is a human growth hormone analog indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency. https://t.me/ppdprogram

➡️Winlevi (clascoterone) Cream Date of Approval: August 26, 2020 Company: Cassiopea SpA Treatment for: Acne Winlevi (clascoterone) cream is a first-in-class topical androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. https://t.me/ppdprogram

➡️Evrysdi (risdiplam) for Oral Solution Date of Approval: August 7, 2020 Company: Genentech Treatment for: Spinal Muscular Atrophy Evrysdi (risdiplam) is a survival of motor neuron 2 (SMN2) splicing modifier indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. https://t.me/ppdprogram

➡️Mycapssa (octreotide) Delayed-Release Capsules Date of Approval: June 26, 2020 Company: Chiasma, Inc. Treatment for: Acromegaly Mycapssa (octreotide) is an oral formulation of the approved somatostatin analog octreotide for the treatment of acromegaly. https://t.me/ppdprogram

➡️Fintepla (fenfluramine) Oral Solution Date of Approval: June 25, 2020 Company: Zogenix, Inc. Treatment for: Dravet Syndrome, Lennox-Gastaut Syndrome Fintepla (fenfluramine) is an amphetamine derivative indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients 2 years of age and older. https://t.me/ppdprogram

➡️Gimoti (metoclopramide) Nasal Spray Date of Approval: June 19, 2020 Company: Evoke Pharma, Inc. Treatment for: Gastroparesis Gimoti (metoclopramide) is an intranasal formulation of the approved drug metoclopramide for the relief of symptoms of acute and recurrent diabetic gastroparesis in adults. https://t.me/ppdprogram

➡️Lyumjev (insulin lispro-aabc) Injection Date of Approval: June 15, 2020 Company: Eli Lilly and Company Treatment for: Diabetes, Type 1, Diabetes, Type 2 Lyumjev (insulin lispro-aabc) is a rapid-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. https://t.me/ppdprogram

➡️Semglee (insulin glargine-yfgn) Injection Date of Approval: June 11, 2020 Company: Mylan Pharmaceuticals Inc. Treatment for: Diabetes, Type 1, Diabetes, Type 2 Semglee (insulin glargine-yfgn) is a long-acting human insulin analog biosimilar to Lantus (insulin glargine) indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus, and adults with type 2 diabetes mellitus. https://t.me/ppdprogram

➡️Zilxi (minocycline) Topical Foam - formerly FMX103 Date of Approval: May 28, 2020 Company: Foamix Pharmaceuticals Ltd. Treatment for: Rosacea Zilxi (minocycline) is a topical tetracycline formulation indicated for the treatment of inflammatory lesions of rosacea in adults. https://t.me/ppdprogram